Pathogen Reduction Device Shows Efficacy Against Virus Causing COVID-19 in Plasma and Platelets  
Terumo BCT's Mirasol shows efficacy against virus causing COVID-19 in plasma and platelets. (Photos: Terumo BCT)

Blood

Pathogen Reduction Device Shows Efficacy Against Virus Causing COVID-19 in Plasma and Platelets  

22 Apr, 2020

Published over 6 years ago. See the latest and most current information on Blood.

Data from a new study suggests that a medical device that uses vitamin B2 and ultraviolet light for treating human blood products is effective against the virus that causes COVID-19. The study results, generated by Terumo BCT in collaboration with top researchers from Colorado State University, have been accepted for publication by Vox Sanguinis, a peer-reviewed medical journal covering haematology.

Blood is considered vital medicine, and it is the backbone of the healthcare system. While there is no evidence that blood transfusions transmit COVID-19, some blood centres are using Mirasol to treat platelets and plasma as an additional layer of safety.

In some parts of the world, healthcare providers also treat convalescent plasma with Mirasol. The International Society for Blood Transfusion (ISBT) Global Blood Safety Working Party recommends, where feasible, pathogen inactivation of plasma to control residual risks of transfusion transmitted infection diseases and to ally concern about possible super infections with SARS-CoV-2, the virus that causes COVID-19.2

Using riboflavin (vitamin B2) and ultraviolet light, Mirasol is designed to reduce the pathogen load of various disease-causing agents such as viruses, parasites and bacteria in blood products before they are transfused to patients. Mirasol also inactivates white blood cells to help reduce certain transfusion reactions.

“Mirasol is one of the tools we are using to help equip healthcare providers in their fight against COVID-19,” said Antoinette Gawin, President and Chief Executive Officer, Terumo BCT. “We are deploying our existing innovations to benefit as many patients as possible.”

Mirasol is CE marked for platelets, plasma and whole blood and is in routine use in more than 20 countries throughout Europe, the Middle East, Africa, Asia and Latin America. The system is not approved for sale in the US and Canada.

There are no approved devices or therapies for specific treatment of COVID-19. 

More information online

Lab Asia 33.4 - August 2026

Explore our Digital Edition

Discover the latest news and research

Digital edition

Explore Our Other Sites

Envirotech Online
FM approval strengthens intelligent fixed gas detection for refineries and petrochemical plants
Explore more Arrow
Pollution Solutions Online
Valmet to deliver automation system for CO₂ liquefaction plant advancing Finland's green transition
Explore more Arrow
Petro Online
Why more industries are moving beyond fixed oil change schedules
Explore more Arrow
Chromatography Today
Unlock high-resolution analysis of therapeutic oligonucleotides
Explore more Arrow